 |
Hold (2.00 out of 4)
0th percentile
|
|
|
 Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Friday, February 7, 5:17 AM
Slide #204. Matinas BioPharma Holdings, Inc. — Preferred Stock Offering
| Company: |
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) |
| Date announced: |
6/19/2018 |
| Shares Offered: |
8,000 |
| Date of Pricing: |
6/19/2018 |
| Price Per Share: |
$1,000.00 |
| Preferred Stock Offering Details: |
Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its proprietary lipid nano-crystal (LNC) platform technology, today announced the pricing of a public offering of up to 8,000 shares of its newly designated Series B Convertible Preferred Stock, or the Series B Preferred, with a stated value of $1,000 per share and convertible into an aggregate of 16,000,000 shares of its common stock at a conversion price of $0.50 per share. Holders of the Series B Preferred will be entitled to receive dividends payable in shares of common stock equal to (i) 10% of the shares of common stock underlying the Series B Preferred then held by such holder on the 12-month anniversary of the offering, (ii) 15% of the shares of common stock underlying the Series B Preferred then held by such holder on the 24-month anniversary of the offering and (iii) 20% of the shares of common stock underlying the Series B Preferred then held by such holder on the 36-month anniversary of the offering. |
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. Co. is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
 Open the MTNB Page at Preferred Stock Channel »
Open the MTNB Page at Preferred Stock Channel (in a new window) »
|
|
Free MTNB Email Alerts:
